64

Señor

SUPERINTENDENTE DE INDUSTRIA Y COMERCIO

DIVISION DE NUEVAS CREACIONES

E. S. D.

SUPERINDUSTRIA Y COMERCIO
Radicacion : 00044225 00000001 Folios: 84
Fecha (AMD): 2000-08-11 16:29:43
Tramite : 002 PATENTES D 1 REGISTRO/ 329 COMPLEMEN
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

Re: P1.-**ASTRAZENECA AB.-** Solicitud de Patente de Invención para **"NUEVOS COMPUESTOS BISPIDINA UTILES EN EL TRATAMIENTO DE ARRITMIAS CARDIACAS"**.- Clase A61.- Expediente número 00-044.225.-

1. Me refiero a mi solicitud arriba nombrada de 14 de Junio de 2000.

2. Anexos me permito presentar a usted:

(1) Copia autentica, debidamente certificada de la solicitud de patente presentada para el invento arriba nombrado **respecto de la cual reclamo prioridad,** a saber la solicitud sueca número 9902271-7 de 16 de Junio de 1999, junto con su Traducción Oficial correspondiente a las legalizaciones y reivindicaciones;


(2) Copia debidamente autenticada por el Notario Sexto del Circulo de Bogotá, de los documentos que acreditan la calidad de Traductor Oficial de la señora María Luisa Brigard de Restrepo, quien elaboró la traducción de las legalizaciones y reivindicaciones de la solicitud sueca número 9902271-7 de 16 de Junio de 1999;

(3) Documento que acredita el traspaso que los autores del invento de la referencia hacen a favor de mi poderdante, de sus derechos sobre el mismo, debidamente legalizado hasta por el Ministerio de Relaciones Exteriores de Colombia bajo los números 083468 de 21 de Junio de 2000 y 182198 de 14 de Junio de 2000; y

(4) Traducción Oficial No. 142, debidamente legalizada hasta por el Ministerio de Relaciones Exteriores de Colombia bajo el número 284303 de 20 de Junio de 2000, correspondiente a las legalizaciones de dicho documento de traspaso.

3. Ruego a usted tomar atenta nota de lo anterior y proceder de conformidad.

Señor Superintendente,



JOSE ANTONIO LLOREDA
T.P. 10.784
Código 231

~~85~~

67

TRADUCCION OFICIAL No. 5.726

de un documento escrito en INGLES, el cual para su identificación se sella con el sello del Traductor al mismo tiempo que la presente. -

---

PRV

DIRECCION NACIONAL DE PATENTES Y REGISTRO

Certificado

TRADUCCION OFICIAL No. 5.726

Por el presente se certifica que la anexa es una copia fiel de los documentos registrados originalmente ante la Oficina de Patentes y Registro en relación con la siguiente solicitud de patente.

La solicitud fue registrada originalmente en inglés.

(71) Solicitante(s) Astra AB, Södertälje SE

(21) Solicitud de patente número 9902271-7

(86) Fecha de registro 16-6-1999

Estocolmo, 16-5-2000

68

Por la Oficina de Patentes y Registro

(Firma)

Anita Södervall

Derechos 170:-

No. 6180

El Ministerio de Relaciones Exteriores en Estocolmo certifica por la presente que Anita Södervall - Oficina de Patentes y Registro Sueca - expidió y firmó la certificación que antecede en su carácter oficial.

Derechos Estocolmo, hoy 24 de mayo del 2000

Kr 110= PAGADOS

Firma)

Agneta Söderlund


Sello: MINISTERIO DE RELACIONES EXTERIORES

EN ESPAÑOL, las autenticaciones de la firma anterior hasta por el Ministerio de Relaciones Exteriores de Colombia bajo el número de fecha de junio del 2.000

ANEXO:

Reivindicaciones

1. Un compuesto de la fórmula I,



TRADUCCIÓN OFICIAL No. 5726
María Luisa Briceño de Restrepo
Intérprete Oficial

I

en donde

R^1 representa alquilo C_{1-12}, $-(CH_2)_a$-arilo, o $(CH_2)_a$-Het^1 (todos ellos opcionalmente sustituidos y/o terminados (según sea adecuado) por uno o más sustitutos escogidos entre -OH, halo, nitro, alquilo C_{1-4} y/o alcoxi C_{1-4};

a representa 0, 1, 2, 3 o 4;

Het^1 representa un anillo heterocíclico de cinco a diez miembros que contiene uno o varios

heteroátomos escogidos entre oxígeno, nitrógeno y/o azufre e incluye también opcionalmente uno o varios sustitutos =O;

X representa O o S;

R^{5a} y R^{5b} representan, independientemente, H o alquilo C_{1-3};

R^2 y R^3 representan, independientemente, H, alquilo C_{1-4} (opcionalmente sustituido y/o terminado con uno o más grupos nitro o ciano), OR^7, $N(R^{7a})R^{7b}$, $OC(O)R^8$ o juntos forman $-O-(CH_2)_2-O-$, $-(CH_2)_3-$, $-(CH_2)_4-$ o $-(CH_2)_5-$;

5726

PUBLICACION OFICIAL
María Laura Brizard de Rodrigo
Intérprete Oficial

R^7 y R^8 representan, independientemente, H, alquilo C_{1-6} o arilo $(CH_2)_b$ (los dos últimos grupos opcionalmente sustituidos y/o terminados por uno o varios sustitutos escogidos entre -OH, halo, ciano, alquilo C_{1-4} y/o alcoxi C_{1-4});

R^{7a} y R^{7b} representan, independientemente, H o alquilo C_{1-6};

b representa 0, 1, 2, 3 o 4;

R^4 representa H o alquilo C_{1-6};

R^9 representa $-C(O)R^{10}$, alquilo C_{1-6}, $(CH_2)_d$-arilo, o $-(CH_2)_d$-Het^2 (estos dos últimos grupos opcionalmente sustituidos y/o terminados (según sea adecuado) por uno o varios sustitutos escogidos entre -OH, ciano, halo, amino, nitro, alquilo C_{1-6}, alcoxi C_{1-6}, $-C(O)R^{14}$, -

$C(O)R^{15}$ y/o $N(H)S(O)_2R^{16}$);

R^{10}, R^{11} y R^{12} representan, independientemente, H, alquilo C_{1-6}, Het^2 o $(CH_2)_f$-arilo (estos tres últimos grupos opcionalmente sustituidos y/o terminados (según sea adecuado) por uno o varios sustitutos escogidos entre -OH, ciano, halo, amino, nitro, alquilo C_{1-6} ,alcoxi C_{1-6}, $-C(O)R^{14}$, $-C(O)R^{15}$ y/o $N(H)S(O)_2R^{16}$);

R^{13} representa alquilo C_{1-6} o $(CH_2)_g$-arilo (ambos grupos opcionalmente sustituidos y/o terminados (según sea adecuado) por uno o varios sustitutos escogidos entre halo, nitro, alquilo C_{1-6} y/o alcoxi C_{1-6};

5.726

María Luisa Brigard de Restrepo
Intérprete Oficial

R^{14} y R^{15} representan, independientemente, H, alquilo C_{1-6} o arilo;

R^{16} representa alquilo C_{1-6} o arilo;

c representa 0, 1 o 2;

d, *f* y *g* representan, independientemente, 0, 1, 2, 3 o 4;

Het^2 y Het^2 representan, independientemente, anillos heterocíclicos de cinco a diez miembros que contienen uno o varios heteroátomos escogidos entre oxígeno, nitrógeno y/o azufre, e incluyen también opcionalmente uno o varios sustitutos =O;

R^6 representa uno o varios sustitutos opcionales escogidos entre -OH, ciano, halo, amino,

nitro, alquilo C_{1-6} (opcionalmente terminado por $N(H)S(O)_2R^{18a}$), alcoxi C_{1-6} , -$C(O)N(H)R^{19}$, $NHC(O)N(H)R^{20}$, $N(H)S(O)_2R^{21}$ y/o $-OS(O)_2R^{22}$;

R^{19} y R^{20} representan, independientemente, H o alquilo C_{1-6} ;

R^{18a}, R^{21} y R^{22} representan, independientemente, alquilo C_{1-6} ;

A representa un enlace simple, alquileno C_{1-6} o $-(CH_2)_jC(H)(OR^{23})-(CH_2)_k-$ (en este último grupo el grupo $-(CH_2)_j-$ está unido al átomo de nitrógeno de bispidina y los dos últimos grupos están sustituidos opcionalmente por uno o varios grupos -OH);

B representa un enlace simple, alquileno C_{1-4} , $(CH_2)_mN(R^{24})-$, $(CH_2)_mS(O)_n-$, $(CH_2)_mO$ (en estos tres últimos grupos, el grupo $-(CH_2)_m-$ está unido al átomo de carbono que lleva OR^9 y R^4), $N(R^{24})(O)O(CH_2)_m-$ o $N(R^{24})(CH_2)_m-$ (en estos dos últimos grupos el grupo $N(R^{24})$ está unido al átomo de carbono que lleva OR^9 y R^4);

j representa 1, 2, 3 o 4;

k y *m* representan, independientemente, 1, 2, 3 o 4;

n representa 0, 1 o 2;

R^{23} representa H, alquilo C_{1-6} o $C(O)R^{25}$;

R^{24} representa H o alquilo C_{1-6};

R^{25} representa H, alquilo C_{1-6}, Het^4 o $(CH_2)_g$-arilo (estos dos últimos grupos opcionalmente sustituidos y/o terminados (según sea adecuado) por uno o varios sustitutos escogidos entre -OH, ciano, halo, amino, nitro, alquilo C_{1-6} y/o alcoxi C_{1-6};

Het^4 representa un anillo heterocíclico de cinco a diez miembros que contiene uno o varios heteroátomos escogidos entre oxígeno, nitrógeno y/o azufre, e incluye también opcionalmente uno o varios sustitutos =O;

5.726
...OFICIAL No.
María Luisa Brigard de Restrepo
Intérprete Oficial

p representa 0, 1, 2, 3 o 4;

o un derivado farmaceuticamente aceptable del mismo;

con la condición de que:

m no representa 0 cuando B representa $-(CH_2)_m-N(R^{24})-$, $-(CH_2)_m-S(O)_n-$ o $-(CH_2)_m-O-$.

2. Un compuesto como el reivindicado en la Reivindicación 1, en el que R^1 representa $-(CH_2)_a$-fenilo opcionalmente sustituido, en el que *a* es 0, 1, 2 o 3, o alquilo C_{1-18} opcionalmente sustituido, opcionalmente insaturado, lineal, ramificado o cíclico (grupo este último que puede estar también interrumpido por un átomo de oxígeno).

3. Un compuesto como el reivindicado en cualquiera de las Reivindicaciones 1 o 2, en el que R^2 representa H.

4. Un compuesto como el reivindicado en cualquiera de las reivindicaciones que anteceden, en el que R^3 representa H.

5. Un compuesto como el reivindicado en cualquiera de las reivindicaciones que anteceden, en el que R^4 representa H, o alquilo C_{1-2}.

5.726
OFICINA ESPAÑOLA DE PATENTES Y MARCAS
Clase Internacional de la Oficina Española de Patentes y Marcas

6. Un compuesto como el reivindicado en cualquiera de las reivindicaciones que anteceden, en el que uno cualquiera de los radicales R^{5a} y R^{5b} representa H, o ambos representan metilo.

7. Un compuesto como el reivindicado en cualquiera de las reivindicaciones que anteceden, en el que R^6 representa representa uno o varios sustitutos escogidos entre alquilo C_{1-6}, ciano, nitro, amino -$C(O)N(H)R^{19}$ y/o $N(H)S(O)_2R^{21}$.

8. Un compuesto como el reivindicado en cualquiera de las reivindicaciones que anteceden, en el que X representa O.

9. Un compuesto como el reivindicado en cualquiera de las reivindicaciones que anteceden, en el que A representa un enlace simple o alquileno C_{1-6} lineal o ramificado (grupo este que está también opcionalmente interrumpido por O).

10. Un compuesto como el reivindicado en cualquiera de las reivindicaciones que anteceden, en el que B representa un enlace simple, alquileno C_{1-4}, $-(CH_2)_mO-$ o $-(CH_2)_m N(R^{24})-$ (siendo *m* en estos dos últimos casos 1, 2 o 3).

11. Un compuesto como el reivindicado en cualquiera de las reivindicaciones que anteceden, en el que R^9 representa $-C(O)R^{10}$ (en donde R^{10} representa alquilo C_{1-3} u, opcionalmente, Het^3), alquilo C_{1-3}, fenilo opcionalmente sustituido, o $-(CH_2)_d$-Het^2 opcionalmente sustituido (en donde *d* es 0, 1 o 2).

12. Una preparación farmacéutica que incluye un compuesto como el definido en una cualquiera de las Reivindicaciones 1 a 11 en mezcla con un coadyuvante, diluyente o portador farmaceuticamente aceptable.

13. Una preparación farmacéutica para el uso en la profilaxis o el tratamiento de una arritmia, que comprende un compuesto como el definido en una cualquiera de las Reivindicaciones 1 a 11.

14. Un compuesto como el reivindicado en cualquiera de las Reivindicaciones 1 a 11 para el uso como un producto farmacéutico.

15. Un compuesto como el reivindicado en cualquiera de las Reivindicaciones 1 a 11 para el uso en la profilaxis o el tratamiento de una arritmia.

16. El uso de un compuesto como el reivindicado en cualquiera de las Reivindicaciones


1 a 11 como ingrediente activo en la fabricación de un medicamento para el uso en la profilaxis o el tratamiento de una arritmia.

17. El uso reivindicado en la Reivindicación 16 en el que la arritmia es una arritmia atrial o ventricular.

18. Un método de profilaxis o tratamiento de una arritmia, que comprende la administración de una cantidad terapeuticamente efectiva de un compuesto como el definido en una cualquiera de las Reivindicaciones 1 a 11 a una persona que sufre de tal situación o es susceptible a ella.

19. Un procedimiento para la preparación de un compuesto de la fórmula I definida en la Reivindicación 1, que consiste en:

(a) hacer reaccionar un compuesto de la fórmula II



II


en donde R^2, R^3, R^4, R^{5a}, R^{5b}, R^6, R^9, A, y B corresponden a las definiciones dadas en la Reivindicación 1,

con un compuesto de la fórmula III

$$R^1XC(O)L^1 \qquad \text{III}$$

en donde L^1 representa un grupo saliente y R^1 y X corresponden a las definiciones dadas en la Reivindicación 1;


(b) hacer reaccionar un compuesto de la fórmula IV,



IV

en donde R^1, R^2, R^3, R^{5a}, R^{5b}, y X corresponden a las definiciones dadas en la Reivindicación 1,

con un compuesto de la fórmula V,




V

en donde L^2 representa un grupo saliente y R^4, R^6, R^9, A y B corresponden a las definiciones dadas en la Reivindicación 1;

(c) para los compuestos de la fórmula I en los que uno de los radicales R^2 y R^3 representa H o bien OH y el otro representa H,

reducir un compuesto correspondiente de la fórmula VI,




VI

en donde R^1, R^4, R^{5a}, R^{5b}, R^6, R^9, A, B y X corresponden a las definiciones dadas en la Reivindicación 1;

(d) para los compuestos de la fórmula I en los que R^9 representa alquilo C_{1-6} opcionalmente sustituido, $-(CH_2)_d$-arilo opcionalmente sustituido o $(CH_2)_d$-Het^2 opcionalmente sustituido,

hacer reaccionar un compuesto de la fórmula VII



GACETA OFICIAL No. 5.726

en donde R^1, R^2, R^3, R^4, R^{5a}, R^{5b}, R^6, A y B corresponden a las definiciones dadas en la Reivindicación 1;


con un compuesto de la fórmula VIII,

$$R^{9a}OH \qquad \text{VIII}$$

en donde R^{9a} representa alquilo C_{1-6} opcionalmente sustituido, $-(CH_2)_d$-arilo opcionalmente sustituido o $(CH_2)_d$-Het^2 opcionalmente sustituido y *d* y Het^2 corresponden a las definiciones dadas en la Reivindicación 1;

(e) para los compuestos de la fórmula I en los que R^9 representa alquilo C_{1-6} opcionalmente sustituido, $-(CH_2)_d$-arilo opcionalmente sustituido o $(CH_2)_d$-Het^2 opcionalmente sustituido,

hacer reaccionar un compuesto de la fórmula IX



IX

en donde L^2 corresponde a la definición dada arriba y R^1, R^2, R^3, R^4, R^{5a}, R^{5b}, R^6, A y B corresponden a las definiciones dadas en la Reivindicación 1,

con un compuesto de la fórmula VIII definida arriba;

(f) para los compuestos de la fórmula 1 en los que R^9 representa $C(O)R^{10}$ y R^{10} corresponde a la definición dada en la Reivindicación 1,

hacer reaccionar un compuesto de la fórmula VII definida arriba, con un compuesto de la fórmula X,

$R^{10}CO_2H$ X

en donde R^{10} corresponde a la definición dada en la Reivindicación 1;

(g) para los compuestos de la fórmula 1 en los que R^2 y/o R^3 representan $OC(O)R^8$ y R^8 corresponde a la definición dada en la Reivindicación 1

reunir un compuesto correspondiente de la fórmula 1 en el que R^2 y/o R^3 (según sea adecuado) representan OH y un compuesto de la fórmula XI

726

María Luisa Brigero de Restrepo
Intérprete Oficial

R^8CO_2H XI

en donde R^8 corresponde a la definición dada en la Reivindicación 1;

(h) para los compuestos de la fórmula 1 que son derivados de N-óxido de bispidina-nitrógeno,

oxidar el nitrógeno de bispidina correspondiente de un compuesto correspondiente de la fórmula 1;

(i) para los compuestos de la fórmula 1 que son derivados de sal de amonio cuaternario de alquilo C_{1-4}, en los que el grupo alquilo está unido a un nitrógeno de bispidina,

hacer reaccionar, en el nitrógeno de bispidina, de un compuesto correspondiente de la

fórmula 1 con un compuesto de la fórmula XII,

$$R^aHal \qquad XII$$

en donde R^a representa alquilo C_{1-4} y Hal representa Cl, Br o I;

(j) hacer reaccionar un compuesto de la fórmula II definida arriba,

con un compuesto de la fórmula XIII

PUBLICACION OFICIAL No. 5726
María Luisa Brigard de Restrepo
Intérprete Oficial

$$R^1XH \qquad XIII$$

en donde R^1 y X corresponden a las definiciones dadas en la Reivindicación 1,

en la presencia de 1,1'-carboxildiimidazola;

(k) para los compuestos de la fórmula 1 en los que uno de los radicales R^2 y R^3, o ambos, representan $-N(R^{7a})R^{7b}$, en donde uno de los radicales R^{7a} y R^{7b}, o ambos, representan alquilo C_{1-6},

alquilar un compuesto correspondiente de la fórmula 1 en el que R^2 y/o R^3 representan $-N(R^{7a})R^{7b}$ (según sea adecuado) en donde R^{7a} y/o R^{7b} (según sea adecuado) representan H,

usando un compuesto de la fórmula XIIIA

$R^{7o}L^1$ XIIIA

en donde R^{7o} representa alquilo C_{11-6} y L^1 corresponde a la definición dada arriba;

(l) convertir un sustituto R^6 en otro; o


(m) desproteger un derivado protegido de un compuesto de la fórmula I definida en la Reivindicación 1.

20. Un compuesto de la fórmula II definida en la Reivindicación 19, o un derivado protegido del mismo.

21. Un compuesto de la fórmula IV definida en la Reivindicación 19, o un derivado protegido del mismo, con la condición de que cuando tanto R^{5a} como R^{5b} representan H, entonces al menos uno de los radicales R^2 y R^3 representa OR^7, $OC(O)R^8$ o alquilo C_{1-4} y este grupo alquilo está sustituido y/o terminado con uno o varios grupos nitro o ciano.

22. Un compuesto de la fórmula VI definida en la Reivindicación 19, o un derivado protegido del mismo.


23. Un compuesto de la fórmula XV,



XV

en donde R^4, R^{5a}, R^{5b}, R^9, A y B corresponden a las definiciones dadas en la Reivindicación 1, o un derivado protegido del mismo.

24. Un procedimiento para la preparación de un compuesto de la fórmula VI, XV, XVII o XXIII, definidas aquí, que comprende la reacción de un compuesto de la fórmula XXV,




XXV

en donde R^2 representa H o -C(O)XR^1 y R^1, R^{5a}, R^{5b} y X corresponden a las definiciones dadas en la Reivindicación 1

con (según sea adecuado) :

(1) un compuesto de la fórmula XXVI,



XXVI

o un derivado protegido del mismo, en donde R^4, R^6, R^9, A y B corresponden a las definiciones dadas en la Reivindicación 1;

o bien

(2) NH_3 (o un derivado protegido de este),

en todos los casos en la presencia de formaldehido.

ES TRADUCCION FIEL Y COMPLETA, de la cual queda copia en los archivos de esta oficina de traducciones, para su confrontación y a la que me remito.

Derechos de Traducción: $171.000,oo

BOGOTA, 13 DE JUNIO DEL 2000.

TRADUCTOR OFICIAL No. 5726

María Luisa Brigard de Restrepo
Intérprete Oficial
Res. No. 0782 del Min. de Justicia

JOSE LLOREDA CAMACHO & CO

102
86

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

Intyg
Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) *Sökande* / *Applicant (s)* — *Astra AB, Södertälje SE*

(21) *Patentansökningsnummer* / *Patent application number* — *9902271-7*

(86) *Ingivningsdatum* / *Date of filing* — *1999-06-16*

PRODUCTION OFFICIAL No. 5.726
Maria Luisa Bridgard de Restrepo
Intérprete Oficial

Stockholm, 2000-05-16

För Patent- och registreringsverket
For the Patent- and Registration Office

Anita Södervall

Avgift
Fee 170:-

No. 6180
The Ministry for Foreign Affairs in Stockholm, hereby certifies that
Mrs Anita Södervall
The Swedish Patent and Registration Office
has issued and signed the foregoing attestation. In his/her official capacity

Fee Kr 170:- PAID

Stockholm this 16th day of May 2000

Agneta Södervall
Agneta Södervall

23

No. 6427
The Ministry for Foreign Affairs in Stockholm, hereby certifies that
Mrs Agneta Söderlund,
The Swedish Patent and Registration Office
has issued and signed the foregoing attestation in his/her official capacity

Fee Stockholm this 24th day of May
Kr PAID 20 00

120.-

Agneta Söderlund

5.726

EL CONSULADO DE COLOMBIA EN ESTOCOLMO, SUECIA

Fecha 2000-05-26 No: .....

Previa la confrontación correspondiente DA FE de que la(s) firma(s) que aparece(n) en este documento es(son) la(s) REGISTRADA aquí por Agneta Söderlund, Mrs. Relaciones Exteriores, Estocolmo, Suecia.

PAGADO
Impuesto de Timbre Siete dólares US$ 7
Derechos Consulares Quince dólares US$ 15

CONSULADO DE COLOMBIA ESTOCOLMO

.....
MARIA SMITH RUEDA
Encargada de las Funciones Consulares

PRJ99-06-16

PHARMACEUTICALLY ACTIVE COMPOUNDS

Field of the Invention

This invention relates to novel pharmaceutically useful compounds, in particular compounds which are useful in the treatment of cardiac arrhythmias.

Background and Prior Art

Cardiac arrhythmias may be defined as abnormalities in the rate, regularity, or site of origin of the cardiac impulse or as disturbances in conduction which causes an abnormal sequence of activation. Arrhythmias may be classified clinically by means of the presumed site of origin (i.e. as supraventricular, including atrial and atrioventricular, arrhythmias and ventricular arrhythmias) and/or by means of rate (i.e. bradyarrhythmias (slow) and tachyarrhythmias (fast)).

In the treatment of cardiac arrhythmias, the negative outcome in clinical trials (see, for example, the outcome of the Cardiac Arrhythmia Suppression Trial (CAST) reported in New England Journal of Medicine, **321**, 406 (1989)) with "traditional" antiarrhythmic drugs, which act primarily by slowing the conduction velocity (class I antiarrhythmic drugs), has prompted drug development towards compounds which selectively delay cardiac repolarization, thus prolonging the QT interval. Class III antiarrhythmic drugs may be defined as drugs which prolong the trans-membrane action potential duration (which can be caused by a block of outward K^+ currents or from an increase of inward ion currents) and refractoriness, without affecting cardiac conduction.

One of the key disadvantages of hitherto known drugs which act by delaying repolarization (class III or otherwise) is that they all are known to exhibit a unique form of proarrhythmia known as *torsades de pointes* (turning of points), which may, on occasion be fatal. From the point of view of safety, the minimisation of this phenomenon (which has also been shown to be exhibited as a result of administration of non-cardiac drugs such as phenothiazines, tricyclic antidepressants, antihistamines and antibiotics) is a key problem to be solved in the provision of effective antiarrhythmic drugs.

Antiarrhythmic drugs based on bispidines (3,7-diazabicyclo[3.3.1]nonanes), are known from *inter alia* international patent application WO 91/07405, European patent applications 306 871, 308 843 and 655 228 and US patents 3,962,449, 4,556,662, 4,550,112, 4,459,301 and 5,468,858, as well as journal articles including *inter alia* J. Med. Chem. **39**, 2559, (1996), Pharmacol. Res., **24**, 149 (1991), Circulation, **90**, 2032 (1994) and Anal. Sci. **9**, 429, (1993). Known bispidine-based antiarrhythmic compounds include bisaramil (3-methyl-7-ethyl-9α,4′-(Cl-benzoyloxy)-3,7-diazabicyclo[3.3.1]nonane), tedisamil (3′,7′-bis(cyclopropylmethyl)spiro-(cyclopentane-1,9′-3,7]diazabicyclo-[3.3.1]nonane), SAZ-VII-22 (3-(4-chlorobenzoyl)-7-isopropyl-3,7-diazabicyclo[3.3.1]nonane), SAZ-VII-23 (3-benzoyl-7-isopropyl-3,7-diazabicyclo[3.3.1]nonane), GLG-V-13 (3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nonane), KMC-IV-84 (7-[4′-(1*H*-imidazolo-1-yl)benzenesulfonyl]-3-isopropyl-3,7-diaza-bicyclo[3.3.1]nonane dihydro-perchlorate and ambasilide (3-(4-aminobenzoyl)-7-benzyl-3,7-diazabicyclo[3.3.1]nonane).


We have surprisingly found that a novel group of bispidine-based compounds exhibit electrophysiological activity, preferably class III

PRJ99-06-16

electrophysiological activity, and are therefore expected to be useful in the treatment of cardiac arrhythmias.

Disclosure of the Invention

According to the invention there is provided compounds of formula I,



I

wherein

R^1 represents C_{1-12} alkyl, $-(CH_2)_a$-aryl, or $-(CH_2)_a$-Het^1 (all of which are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, halo, cyano, nitro, C_{1-4} alkyl and/or C_{1-4} alkoxy);

a represents 0, 1, 2, 3, or 4;

Het^1 represents a five to ten-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

X represents O or S;

R^{5a} and R^{5b} independently represent H or C_{1-3} alkyl;

R^2 and R^3 independently represent H, C_{1-4} alkyl (optionally substituted and/or terminated with one or more nitro or cyano groups), OR^7, $N(R^{7a})R^{7b}$, $OC(O)R^8$ or together form $-O-(CH_2)_2-O-$, $-(CH_2)_3-$, $-(CH_2)_4-$ or $-(CH_2)_5-$;

R^7 and R^8 independently represent H, C_{1-6} alkyl or $-(CH_2)_b$-aryl (which latter two groups are optionally substituted and/or terminated by one or more substituents selected from -OH, halo, cyano, nitro, C_{1-4} alkyl and/or C_{1-4} alkoxy);

R^{7a} and R^{7b} independently represent H or C_{1-6} alkyl;

b represents 0, 1, 2, 3 or 4;

R^4 represents H or C_{1-6} alkyl;

R^9 represents $-C(O)R^{10}$, C_{1-6} alkyl, $-(CH_2)_d$-aryl or $-(CH_2)_d$-Het^2 (which latter three groups are optionally substituted by one or more substituents selected from -OH, halo, cyano, nitro, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)R^{11}$, $C(O)OR^{12}$ and/or $-N(H)S(O)_eR^{13}$);

R^{10}, R^{11} and R^{12} independently represent H, C_{1-6} alkyl, Het^3 or $-(CH_2)_f$-aryl (which latter three groups are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl, C_{1-6} alkoxy, $C(O)R^{14}$, $C(O)OR^{15}$ and/or $N(H)S(O)_2R^{16}$);

R^{13} represents C_{1-6} alkyl or $-(CH_2)_g$-aryl (both of which are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from halo, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

R^{14} and R^{15} independently represent H, C_{1-6} alkyl or aryl;

R^{16} represents C_{1-6} alkyl or aryl;

e represents 0, 1 or 2;

d, f and g independently represent 0, 1, 2, 3 or 4;

Het^2 and Het^3 independently represent five to ten-membered heterocyclic rings containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

R^6 represents one or more optional substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl (optionally terminated by $N(H)C(O)OR^{18a}$), C_{1-6} alkoxy, $-C(O)N(H)R^{19}$, $-NHC(O)N(H)R^{20}$, $-N(H)S(O)_2R^{21}$ and/or $-OS(O)_2R^{22}$;

R^{19} and R^{20} independently represent H or C_{1-6} alkyl;

R^{18a}, R^{21} and R^{22} independently represent C_{1-6} alkyl;

A represents a single bond, C_{1-6} alkylene or $-(CH_2)_jC(H)(OR^{23})(CH_2)_k$- (in which latter group, the $-(CH_2)_j$- group is attached to the bispidine nitrogen atom and which latter two groups are optionally substituted by one or more -OH groups);

B represents a single bond, C_{1-4} alkylene, $-(CH_2)_mN(R^{24})$-, $-(CH_2)_mS(O)_n$-, $-(CH_2)_mO$- (in which three latter groups, the $-(CH_2)_m$- group is attached to the carbon atom bearing OR^9 and R^4), $-C(O)N(R^{24})$- (in which latter group, the -C(O)- group is attached to the carbon atom bearing OR^9 and R^4), $-N(R^{24})C(O)O(CH_2)_m$- or $-N(R^{24})(CH_2)_m$- (in which latter two groups, the $N(R^{24})$ group is attached to the carbon atom bearing OR^9 and R^4);

j represents 1, 2, 3 or 4;

k and m independently represent 0, 1, 2, 3 or 4;

n represents 0, 1 or 2;

R^{23} represents H, C_{1-6} alkyl or $C(O)R^{25}$;

R^{24} represents H or C_{1-6} alkyl;

R^{25} represents H, C_{1-6} alkyl, Het^4 or $-(CH_2)_p$-aryl (which latter two groups are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

Het^4 represents a five to ten-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

p represents 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable derivative thereof;

provided that m does not represent 0 when B represents $-(CH_2)_mN(R^{24})-$, $-(CH_2)_mS(O)_n-$ or $-(CH_2)_mO-$,

which compounds are referred to hereinafter as "the compounds of the invention".

Aryl groups that may be mentioned include C_{6-10} aryl groups, such as phenyl, naphthyl and the like. Oxyaryl groups that may be mentioned include C_{6-10} oxyaryl groups, such as oxyphenyl (phenoxy), oxynaphthyl (naphthoxy) and the like. When substituted, aryl and aryloxy groups are preferably substituted by between one and three substituents.

Het^1, Het^2, Het^3 and Het^4 groups that may be mentioned include those containing 1 to 4 heteroatoms (selected from the group oxygen, nitrogen and/or sulfur) and in which the total number of atoms in the ring system is between five and ten. Het (Het^1, Het^2, Het^3 and Het^4) groups may be wholly/partly aromatic in character and may be bicyclic and/or include one or more =O substituents. Heterocyclic groups that may be mentioned include morpholinyl, thiazolyl, oxazolyl, isoxazolyl, cinnolinyl, quinazolinyl, phthalazinyl, purinyl, benzimidazolyl, pyrimindinyl, piperazinyl, pyrazinyl, piperidinyl, pyridinyl, pyrrolinyl, pyrrolidinyl, pyrollidinonyl, triazolyl, imidazolyl, quinolinyl, isoquinolinyl, dioxanyl, benzodioxanyl, benzodioxolyl, benzodioxepanyl, benzomorpholinyl, indolyl, pyrazolyl, pyrrolyl, benzothiophenyl, thiophenyl, chromanyl, thiochromanyl, benzofuranyl, pyranyl, tetrahydropyranyl, tetrahydrofuranyl, furanyl and the like. Values of Het^2 that may be mentioned include pyridinyl. Values of Het^3 that may be mentioned include piperazinyl (which latter group is optionally substituted by one or more $C(O)R^{14}$ and/or $C(O)OR^{15}$ group). Substituents on Het (Het^1, Het^2, Het^3 and Het^4) groups may, where appropriate, be located on any atom in the ring system including a heteroatom. The point of attachment of Het (Het^1, Het^2, Het^3 and Het^4) groups may be *via* any atom in the ring system including (where appropriate) a heteroatom. Het may optionally be in the N- or S-oxidised form.

Pharmaceutically acceptable derivatives include salts and solvates. Salts which may be mentioned include acid addition salts. Pharmaceutically acceptable derivatives also include C_{1-4} alkyl quaternary ammonium salts and N-oxides, provided that, when a N-oxide is present:

(a) no Het (Het^1, Het^2, Het^3, Het^4) groups contain an unoxidised S-atom;

(b) X does not represent S;

(c) n does not represent 0, when B represents $-(CH_2)_mS(O)_n-$; and/or

(d) e does not represent 0, when R^9 is substituted by $-N(H)S(O)_eR^{13}$.

The compounds of the invention may exhibit tautomerism. All tautomeric forms and mixtures thereof are included within the scope of the invention.

The compounds of the invention may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism. Diastereoisomers may be separated using conventional techniques, e.g. chromatography or fractional crystallisation. The various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques. Alternatively the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation or epimerisation, or by derivatisation, for example with a homochiral acid followed by separation of the diastereomeric esters by conventional means (e.g. HPLC, chromatography over silica). All stereoisomers are included within the scope of the invention.

Alkyl groups that R^1, R^2, R^3, R^4, R^{5a}, R^{5b}, R^6, R^7, R^{7a}, R^{7b}, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{18a}, R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, R^{24} and R^{25} may represent, and with which R^1, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13} and R^{25} may be substituted; and alkoxy groups that R^6 may represent, and with which R^1, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13} and R^{25} may be substituted, may be linear or, when there is a sufficient number (i.e. three) of carbon atoms, be branched and/or cyclic. Further, when there is a sufficient number (i.e. four) of carbon atoms, such alkyl and alkoxy groups may also be part cyclic/acyclic. Such alkyl and alkoxy groups may also be saturated or, when there is a sufficient number (i.e. two) of carbon atoms, be

unsaturated and/or interrupted by oxygen and/or substituted by one or more fluoro groups.

Alkylene groups that A and B may represent, and -(CH_2)- containing groups that R^1, R^2 and R^3 (together), R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{25}, A and B may include, may be linear or, when there is a sufficient number (i.e. two) of carbon atoms, be branched. Such alkylene groups and -(CH_2)- containing chains may also be saturated or, when there is a sufficient number (i.e. two) of carbon atoms, be unsaturated and/or interrupted by oxygen.

As used herein, the term "halo" includes fluoro, chloro, bromo or iodo.

Abbreviations are listed at the end of this specification.

Preferred compounds of the invention include those in which:

R^1 represents optionally substituted -(CH_2)$_a$-phenyl, in which a is 0, 1, 2 or 3, or, preferably, optionally substituted, optionally unsaturated, linear, branched or cyclic, C_{1-8} alkyl (which latter group may also be interrupted by an oxygen atom);

R^2 represents H;

R^3 represents H;

R^4 represents H or C_{1-2} alkyl;

R^{5a} and R^{5b} either both represent H or both represent methyl;

R^6 represents one or more substituents selected from C_{1-6} alkyl, cyano, nitro, amino, C(O)N(H)R^{19} and/or -N(H)S(O)$_2R^{21}$;

X represents O;

A represents a single bond or linear, or branched, C_{1-6} alkylene (which group is also optionally interrupted by O);

B represents a single bond, C_{1-4} alkylene, $-(CH_2)_mO-$ or $-(CH_2)_mN(R^{24})-$ (in which latter two cases m is 1, 2 or 3);

R^9 represents $C(O)R^{10}$ (in which R^{10} represents C_{1-3} alkyl or optionally substituted Het^3); C_{1-3} alkyl; optionally substituted phenyl; or optionally substituted $-(CH_2)_d$-Het^2 (in which d is 0, 1 or 2);

when the bispidine nitrogen bearing A optionally bears a C_{1-4} alkyl group, thus forming a quaternary ammonium salt, the alkyl group is a methyl group.

More preferred compounds of the invention include those in which:

R^1 represents linear or branched C_{2-6} alkyl;

R^4 represents H;

R^{5a} and R^{5b} both represent H;

R^6 represents cyano, preferably in the *para* position relative to B;

A represents C_{1-4} alkylene;

B represents a single bond;


R^9 represents $C(O)R^{10}$ (in which R^{10} represents C_{1-2} alkyl or 1,4-piperazinyl (optionally substituted in the 4-position by a $C(O)R^{14}$ or a $C(O)OR^{15}$ group)); C_{1-2} alkyl; phenyl (optionally substituted by one or more groups selected from C_{1-2} alkoxy, OH, halo and/or $N(H)S(O)_2R^{13}$ (in which R^{13} is C_{1-2} alkyl); or $-(CH_2)_d$-Het^2 (in which d represent 0 or 1 and Het^2 represents pyridinyl, optionally in the form of an N-oxide).

Preferred compounds of the invention include the compounds of Examples described hereinafter.

Preparation

According to the invention there is also provided a process for the preparation of compounds of formula I which comprises:

(a) reaction of a compound of formula II,




II

wherein R^2, R^3, R^4, R^{5a}, R^{5b}, R^6, R^9, A and B are as hereinbefore defined with a compound of formula III,

$$R^1XC(O)L^1 \qquad \text{III}$$


wherein L^1 represents a leaving group, such as Hal, imidazolyl or $-OC(O)XR^1$, Hal represents Cl, Br or I, and R^1 and X are as hereinbefore defined, for example at or above room temperature in the presence of a suitable base (e.g. aqueous NaOH, K_2CO_3 or triethylamine) and an appropriate organic solvent (e.g. CH_2Cl_2, THF, acetonitrile, toluene, or mixtures of such solvents);

(b) reaction of a compound of formula IV



IV


wherein R^1, R^2, R^3, R^{5a}, R^{5b} and X are as hereinbefore defined, with a compound of formula V,



V

wherein L^2 represents a leaving group (e.g. mesylate, tosylate or Hal, where Hal is as hereinbefore defined) and R^4, R^6, R^9, A and B are as hereinbefore defined, for example at elevated temperature (e.g. between 35°C and reflux temperature) in the presence of a suitable base (e.g. triethylamine or K_2CO_3) and an appropriate organic solvent (e.g. acetonitrile or dimethylsulfoxide);

(c) for compounds of formula I in which R^2 and R^3 both represent H, reduction of a corresponding compound of formula VI,




VI

wherein R^1, R^4, R^{5a}, R^{5b}, R^6, R^9, A, B and X are as hereinbefore defined, and in which the bridgehead C=O group may be activated using an appropriate agent, such as tosylhydrazine, in the presence of a suitable reducing agent (e.g. sodium borohydride or sodium cyanoborohydride) and an appropriate organic solvent (e.g. a lower alkyl alcohol); when the C=O group is activated, the activation step may be carried out at between room and reflux temperature in the presence of an appropriate organic solvent (e.g. a lower alkyl alcohol such as methanol, ethanol or IPA), whereafter the reducing agent may be added to the reaction mixture and the reduction carried out at between 60°C and reflux, advantageously in the presence of a suitable organic acid (e.g. acetic acid);

(d) for compounds of formula I in which one or R^2 and R^3 represents H and the other represents -OH, reduction of a corresponding compound of formula VI, as hereinbefore defined, in the presence of a mild reducing agent, e.g. sodium borohydride, and an appropriate organic solvent (e.g. a lower alcohol such as methanol or ethanol);

(e) for compounds of formula I in which R^9 represents optionally substituted C_{1-6} alkyl, optionally substituted $-(CH_2)_d$-aryl or optionally substituted $-(CH_2)_d$-Het^2, reaction of a compound of formula VII,




VII

wherein R^1, R^2, R^3, R^4, R^{5a}, R^{5b}, R^6, A and B are as hereinbefore defined with a compound of formula VIII,

$R^{9a}OH$ VIII

wherein R^{9a} represents optionally substituted C_{1-6} alkyl, optionally substituted $-(CH_2)_d$-aryl or optionally substituted $-(CH_2)_d$-Het^2, wherein d and Het^2 are as hereinbefore defined, for example at between ambient (e.g. 25°C) and reflux temperature, under Mitsunobu-type conditions (i.e. in the presence of e.g. triphenylphosphine, an azodicarboxylate derivative (e.g. 1,1'-(azodicarbonyl)dipiperidine) and a suitable organic solvent (e.g. dichloromethane));

(f) for compounds of formula I in which R^9 represents optionally substituted C_{1-6} alkyl, optionally substituted $-(CH_2)_d$-aryl or optionally substituted $-(CH_2)_d$-Het^2, reaction of a compound of formula IX,



IX

wherein L^2, R^1, R^2, R^3, R^4, R^{5a}, R^{5b}, R^6, A and B are as hereinbefore defined with a compound of formula VIII as hereinbefore defined, for example at between ambient (e.g. 25°C) and reflux temperature, under Williamson-type conditions (i.e. in the presence of an appropriate base (e.g. KOH or NaH) and a suitable organic solvent (e.g. dimethylsulfoxide or DMF));

(g) for compounds of formula I in which R^9 represents $C(O)R^{10}$ and R^{10} is as hereinbefore defined, reaction of a corresponding compound of formula VII as hereinbefore defined and a compound of formula X,

$$R^{10}CO_2H \qquad X$$

wherein R^{10} is as hereinbefore defined, for example at ambient temperature (e.g. 25°C) in the presence of a suitable coupling agent (e.g. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide), an appropriate catalyst (e.g. 4-dimethylaminopyridine) and a reaction-inert organic solvent (e.g. THF);

(h) for compounds of formula I in which R^2 and/or R^3 represent represents $OC(O)R^8$ and R^8 is as hereinbefore defined, coupling of a corresponding compound of formula I in which R^2 and/or R^3 (as appropriate) represents OH and a compound of formula XI,

$$R^8CO_2H \qquad XI$$

wherein R^8 is as hereinbefore defined, for example at ambient temperature (e.g. 25°C) in the presence of a suitable coupling agent (e.g. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide), an appropriate catalyst (e.g. 4-dimethylaminopyridine) and a reaction-inert organic solvent (e.g. THF);

(i) for compounds of formula I which are bispidine-nitrogen N-oxide derivatives, oxidation of the corresponding bispidine nitrogen of a corresponding compound of formula I, in the presence of a suitable oxidising agent (e.g. *m*-chloroperbenzoic acid), for example at 0°C in the presence of a suitable organic solvent (e.g. DCM);

(j) for compounds of formula I which are C_{1-4} alkyl quaternary ammonium salt derivatives, in which the alkyl group is attached to a bispidine nitrogen, reaction, at the bispidine nitrogen, of a corresponding compound of formula I with a compound of formula XII,

$$R^xHal \qquad XII$$

wherein R^x represents C_{1-4} alkyl and Hal is as hereinbefore defined, for example at room temperature in the presence of an appropriate organic solvent (e.g. DMF), followed by purification (using e.g. HPLC) in the presence of a suitable counter-ion provider (e.g. NH_4OAc);

(k) reaction of a compound of formula II, as hereinbefore defined, with a compound of formula XIII,

$$R^1XH \qquad XIII$$

PRV99-06-16

wherein R^1 and X are as hereinbefore defined, in the presence of 1,1'-carbonyldiimidazole, for example by refluxing in the presence of a suitable organic solvent (e.g. THF); or


(l) for compounds of formula I in which one or both of R^2 and R^3 represent $-N(R^{7a})R^{7b}$ in which one or both or R^{7a} and R^{7b} represents C_{1-6} alkyl, alkylation of a corresponding compound of formula I in which R^2 and/or R^3 represent $-N(R^{7a})R^{7b}$ (as appropriate) in which R^{7a} and/or R^{7b} (as appropriate) represent H, using a compound of formula XIIIA,

$$R^{7c}L^1 \qquad \text{XIIIA}$$

wherein R^{7c} represents C_{1-6} alkyl and L^1 is as hereinbefore defined, for example under conditions that are well known to those skilled in the art; or

(m) conversion of one R^6 substituent to another using techniques well known to those skilled in the art.

Compounds of formula II may be prepared by reaction of a compound of formula XIV,




XIV

PRV99-06-16

wherein R^2, R^3, R^{5a} and R^{5b} are as hereinbefore defined, with a compound of formula V as hereinbefore defined, for example as described hereinbefore for synthesis of compounds of formula I (process step (b)).

Compounds of formula II in which R^2 and R^3 both represent H may be prepared by reduction of a compound of formula XV,



XV

wherein R^4, R^{5a}, R^{5b}, R^6, R^9, A and B are as hereinbefore defined, and in which the C=O group may be activated using an appropriate agent, such as tosylhydrazine, for example as described hereinbefore for synthesis of compounds of formula I (process step (c)).

Compounds of formula II in which R^2 represents OH and R^3 represents optionally substituted C_{1-4} alkyl, may be prepared by reaction of a compound of formula XV, or a protected derivative thereof, with a compound of formula XVI,

$$R^{3a}MgHal \qquad XVI$$


wherein R^{3a} represents C_{1-4} alkyl (optionally substituted and/or terminated with one or more cyano groups) and Hal is as hereinbefore defined, for example at between -25°C and ambient temperature in the presence of a suitable solvent (e.g. diethyl ether).

PRV99-06-16

Compounds of formula IV may be prepared by reaction of a compound of formula XIV, as hereinbefore defined, with a compound of formula III as hereinbefore defined, for example as described hereinbefore for synthesis of compounds of formula I (process step (a)).

Compounds of formula IV may alternatively be prepared by reaction of a compound of formula XIV, as hereinbefore defined, with a compound of formula XIII, as hereinbefore defined, in the presence of 1,1'-carbonyldiimidazole, for example as described hereinbefore for synthesis of compounds of formula I (process step (k)).

Compounds of formula IV in which R^2 and R^3 represent H may alternatively be prepared by reduction of a corresponding compound of formula XVII,




XVII

wherein R^1, R^{5a}, R^{5b} and X are as hereinbefore defined, and in which the bridgehead C=O group may be activated using an appropriate agent, such as tosylhydrazine, for example as described hereinbefore for compounds of formula I (process step (c)).

Compounds of formula V may be prepared by standard techniques. For example compounds of formula V in which:

PRJ99-06-16

(1) B represents $-(CH_2)_mO-$ may be prepared by coupling a compound of formula XVIII,




XVIII

wherein R^6 is as hereinbefore defined, to a compound of formula XIX,

$$L^4\text{-}(CH_2)_m\text{-}C(OR^9)(R^4)\text{-}A\text{-}L^2 \qquad \text{XIX}$$

wherein L^4 represents a suitable leaving group (e.g. Hal) and Hal, m, R^4, R^9, A and L^2 are as hereinbefore defined;

(2) B represents $-C(O)N(R^{24})-$ may be prepared by coupling a compound of formula XX,



XX

wherein R^6 and R^{24} are as hereinbefore defined, to a compound of formula XXI,

$$L^4\text{-}C(O)\text{-}C(OR^9)(R^4)\text{-}A\text{-}L^2 \qquad \text{XXI}$$


wherein L^4, R^4, R^9, A and L^2 are as hereinbefore defined;

in both cases, under conditions which are well known to those skilled in the art.

Compounds of formula V in which A represents C_2-alkylene and R^9 represents optionally substituted C_{1-6} alkyl, optionally substituted $-(CH_2)_d-$

PRJ99-06-16

aryl or optionally substituted -$(CH_2)_d$-Het^2 may alternatively be prepared by reaction of a compound of formula VIII as hereinbefore defined with a compound of formula XXII,



XXII


wherein R^y represents C_{1-4} alkyl or aryl (which two groups are optionally substituted with one or more substituents selected from C_{1-4} alkyl or halo) and R^4, R^6 and B are as hereinbefore defined, for example at between ambient temperature (e.g. 25°C) and reflux temperature in the presence of a suitable base (e.g. K_2CO_3) and an appropriate organic solvent (e.g. acetonitrile), followed by conversion of the ester functionality to an L^2 group (in which L^2 is as hereinbefore defined), under conditions that are well known to those skilled in the art.

Compounds of formula V in which B represents -$(CH_2)_mS(O)$- or -$(CH_2)_mS(O)_2$- may be prepared by oxidation of a corresponding compound of formula V wherein B represents -$(CH_2)_mS$-, wherein m is as hereinbefore defined, in the presence of an appropriate amount of a suitable oxidising agent (e.g. *m*-chloroperbenzoic acid) and an appropriate organic solvent.

Compounds of formula VII may be prepared in a similar fashion to compounds of formula I (see, for example, process steps (a) or (b)).

Compounds of formula IX may be prepared by replacement of the OH group of a compound of formula VII with an L^2 group under conditions that are well known to those skilled in the art.

Compounds of formula XIV in which R^2 and R^3 both represent H may be prepared by reduction of a compound of formula XXIII,




XXIII

wherein R^{5a} and R^{5b} are as hereinbefore defined, under appropriate conditions (for example conditions such as those described in respect of the preparation of compounds of formula I (process step (c))).

Compounds of formula XIV in which R^2 represents OH and R^3 does not represent H, may be prepared by reaction of a corresponding compound of formula XXIII as hereinbefore defined, with a compound of formula XVI as hereinbefore defined, under appropriate conditions (for example conditions such as those described hereinbefore for the production of compounds of formula II in which R^2 represents OH and R^3 represents R^{3a}).


Compounds of formula XIV in which R^2 and R^3 together represent $-O-(CH_2)_2-O-$, $-(CH_2)_3-$, $-(CH_2)_4-$ or $-(CH_2)_5-$ may be prepared by reduction of a compound of formula XXIV



XXIV


wherein R^{2a} and R^{3a} together represent -O-$(CH_2)_2$-O-, -$(CH_2)_3$-, -$(CH_2)_4$- or -$(CH_2)_5$- and R^{5a} and R^{5b} are as hereinbefore defined in the presence of a suitable reducing agent (e.g. $LiAlH_4$) under conditions that are well known to those skilled in the art.

Compounds of formulae VI, XV, XVII and XXIII may be prepared, advantageously, by reaction of a compound of formula XXV,



XXV

wherein R^z represents H or -C(O)XR^1 and R^1, R^{5a}, R^{5b} and X are as hereinbefore defined, or a protected derivative thereof, with (as appropriate) either (1) a compound of formula XXVI,




XXVI

or a protected derivative thereof, wherein R^4, R^6, R^9, A and B are as hereinbefore defined, or (2) NH_3 (or a protected (e.g. benzyl) derivative thereof), in all cases in the presence of a formaldehyde (i.e. an appropriate source of formaldehyde, such as paraformaldehyde or formalin solution).

The formation of compounds of formulae VI, XV, XVII and XXIII may be carried out in this way for example at between room temperature and reflux (depending upon the concentration of the reactants) in the presence of an appropriate solvent (e.g. ethanol or methanol) and, preferably, in the presence of an organic acid (e.g. a C_{1-6} carboxylic acid, especially acetic acid).

Compounds of formula XXIV may be prepared in accordance with techniques which are well known to those skilled in the art. For example, compounds of formula XXIV in which R^{2a} and R^{3a} together represent $-(CH_2)_3-$, $-(CH_2)_4-$ or $-(CH_2)_5-$ and R^{5a} and R^{5b} are both H may be prepared by reaction of a compound of formula XXVII,



XXVII

wherein $R^{2a'}$ and $R^{3a'}$ together represent $-(CH_2)_3-$, $-(CH_2)_4-$ or $-(CH_2)_5-$, and X, R^1, R^{5a} and R^{5b} are as hereinbefore defined with a mixture of phosphoric acid and sulfuric acid, for example at 120°C.

Compounds of formulae III, VIII, X, XI, XII, XIII, XVI, XVIII, XIX, XX, XXI, XXII, XXV, XXVI and XXVII, and derivatives thereof, are either commercially available, are known in the literature, or may be obtained either by analogy with the processes described herein, or by conventional synthetic procedures, in accordance with standard techniques, from readily available starting materials using appropriate reagents and reaction conditions.

Substituents on the aryl (e.g. phenyl), and (if appropriate) heterocyclic, group(s) in compounds defined herein may be converted to other substituents using techniques well known to those skilled in the art. For example, nitrobenzene may be reduced to an aminobenzene, hydroxy may be converted to alkoxy, alkoxy may be hydrolysed to hydroxy etc.

The compounds of the invention may be isolated from their reaction mixtures using conventional techniques.

It will be appreciated by those skilled in the art that, in the processes described above, the functional groups of intermediate compounds may be, or may need to be, protected by protecting groups.

Functional groups which it is desirable to protect include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl and diarylalkylsilyl groups (e.g. *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl and alkylcarbonyloxy groups (e.g. methyl- and ethylcarbonyloxy groups). Suitable protecting groups for amino include benzyl, *tert*-butyloxycarbonyl, 9-fluorenylmethoxycarbonyl or benzyloxycarbonyl. Suitable protecting groups for carboxylic acid include C_{1-6} alkyl or benzyl esters.

The protection and deprotection of functional groups may take place before or after any of the reaction steps described hereinbefore.

Protecting groups may be removed in accordance with techniques which are well known to those skilled in the art and as described hereinafter.

The use of protecting groups is fully described in "Protective Groups in Organic Chemistry", edited by J W F McOmie, Plenum Press (1973), and "Protective Groups in Organic Synthesis", 2nd edition, T W Greene & P G M Wutz, Wiley-Interscience (1991).

Persons skilled in the art will appreciate that, in order to obtain compounds of the invention in an alternative, and, on some occasions, more convenient, manner, the individual process steps mentioned herein may be performed in a different order, and/or the individual reactions may be performed at a different stage in the overall route (i.e. substituents may be added to and/or chemical transformations performed upon, different intermediates to those associated hereinbefore with a particular reaction). This will depend *inter alia* on factors such as the nature of other functional groups present in a particular substrate, the availability of key intermediates and the protecting group strategy (if any) to be adopted. Clearly, the type of chemistry involved will influence the choice of reagent that is used in the said synthetic steps, the need, and type, of protecting groups that are employed, and the sequence for accomplishing the synthesis.

It will also be appreciated by those skilled in the art that, although certain protected derivatives of compounds of formula I, which may be made prior to a final deprotection stage, may not possess pharmacological activity as

such, they may be administered parenterally or orally and thereafter metabolised in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". Moreover, certain compounds of formula I may act as prodrugs of other compounds of formula I.

All prodrugs of compounds of formula I are included within the scope of the invention.

Some of the intermediates referred to hereinbefore are novel. According to a further aspect of the invention there is thus provided: (a) a compound of formula II as hereinbefore defined or a protected derivative thereof; (b) a compound of formula IV as hereinbefore defined, or a protected derivative thereof, provided that when R^{5a} and R^{5b} both represent H, then at least one of R^2 and R^3 represents OR^7, $OC(O)R^8$ or C_{1-4} alkyl, which alkyl group is substituted and/or terminated with one or more nitro or cyano group; (c) a compound of formula VI, as hereinbefore defined, or a protected derivative thereof; (d) a compound of formula XV, as hereinbefore defined, or a protected derivative thereof.

Medical and pharmaceutical use

The compounds of the invention are useful because they possess pharmacological activity. They are therefore indicated as pharmaceuticals.

Thus, according to a further aspect of the invention there is provided the compounds of the invention for use as pharmaceuticals.

In particular, the compounds of the invention exhibit myocardial electrophysiological activity, for example as demonstrated in the test described below.

The compounds of the invention are thus expected to be useful in both the prophylaxis and the treatment of arrhythmias, and in particular atrial and ventricular arrhythmias.

The compounds of the invention are thus indicated in the treatment or prophylaxis of cardiac diseases, or in indications related to cardiac diseases, in which arrhythmias are believed to play a major role, including ischaemic heart disease, sudden heart attack, myocardial infarction, heart failure, cardiac surgery and thromboembolic events.

In the treatment of arrhythmias, compounds of the invention have been found to selectively delay cardiac repolarization, thus prolonging the QT interval, and, in particular, to exhibit class III activity. Although compounds of the invention have been found to exhibit class III activity in particular, in the treatment of arrhythmias, their mode(s) of activity is/are not necessarily restricted to this class.

According to a further aspect of the invention, there is provided a method of treatment of an arrhythmia which method comprises administration of a therapeutically effective amount of a compound of the invention to a person suffering from, or susceptible to, such a condition.

Pharmaceutical preparations

The compounds of the invention will normally be administered orally, subcutaneously, intravenously, intraarterially, transdermally, intranasally, by inhalation, or by any other parenteral route, in the form of pharmaceutical preparations comprising the active ingredient either as a free base, a pharmaceutically acceptable ion exchanger or a non-toxic organic or inorganic acid addition salt, in a pharmaceutically acceptable dosage form. Depending upon the disorder and patient to be treated, as well as the route of administration, the compositions may be administered at varying doses.

The compounds of the invention may also be combined with any other drugs useful in the treatment of arrhythmias and/or other cardiovascular disorders.

According to a further aspect of the invention there is thus provided a pharmaceutical formulation including a compound of the invention in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

Suitable daily doses of the compounds of the invention in therapeutic treatment of humans are about 0.05 to 5.0 mg/kg body weight at parenteral administration.

The compounds of the invention have the advantage that they are effective against cardiac arrhythmias.

Compounds of the invention may also have the advantage that they may be more efficacious than, be less toxic than, have a broader range of activity (including exhibiting any combination of class I, class II, class III and/or class IV activity (especially class I, class II and/or class IV activity in addition to class III activity)) than, be more potent than, produce fewer side effects (including a lower incidence of proarrhythmias such as *torsades de pointes*) than, be more easily absorbed than, or that they may have other useful pharmacological properties over, compounds known in the prior art.

Biological Tests

Test A

Primary Electrophysiological Effects In Anaesthetised Guinea Pigs

Guinea pigs weighing between 660 an 1100 g were used. The animals were housed for at least one week before the experiment and had free access to food and tap water during that period.

Anaesthesia was induced by an intraperitoneal injection of pentobarbital (40 to 50 mg/kg) and catheters were introduced into one carotid artery (for blood pressure recording and blood sampling) and into one jugular vein (for drug infusions). Needle electrodes were placed on the limbs for recording of ECGs (lead II). A thermistor was placed in the rectum and the animal was placed on a heating pad, set to a rectal temperature of between 37.5 and 38.5°C.

A tracheotomy was performed and the animal was artificially ventilated with room air by use of a small animal ventilator, set to keep blood gases within

PRV98-06-16

the normal range for the species. In order to reduce autonomic influences both vagi were cut in the neck, and 0.5 mg/kg of propranolol was given intravenously, 15 minutes before the start of the experiment.

The left ventricular epicardium was exposed by a left-sided thoracotomy, and a custom-designed suction electrode for recording of the monophasic action potential (MAP) was applied to the left ventricular free wall. The electrode was kept in position as long as an acceptable signal could be recorded, otherwise it was moved to a new position. A bipolar electrode for pacing was clipped to the left atrium. Pacing (2 ms duration, twice the diastolic threshold) was performed with a custom-made constant current stimulator. The heart was paced at a frequency just above the normal sinus rate during 1 minute every fifth minute throughout the study.

The blood pressure, the MAP signal and the lead II ECG were recorded on a Mingograph ink-jet recorder (Siemens-Elema, Sweden). All signals were collected (sampling frequency 1000 Hz) on a PC during the last 10 seconds of each pacing sequence and the last 10 seconds of the following minute of sinus rhythm. The signals were processed using a custom-made program developed for acquisition and analysis of physiological signals measured in experimental animals (see Axenborg and Hirsch, Comput. Methods Programs Biomed. **41**, 55 (1993)).

The test procedure consisted of taking two basal control recordings, 5 minutes apart, during both pacing and sinus rhythm. After the second control recording, the first dose of the test substance was infused in a volume of 0.2 mL into the jugular vein catheter for 30 seconds. Three minutes later, pacing was started and a new recording was made. Five minutes after the previous dose, the next dose of test substance was

administered. Six to ten consecutive doses were given during each experiment.

Data analysis

Of the numerous variables measured in this analysis, three were selected as the most important for comparison and selection of active compounds. The three variables selected were the MAP duration at 75 percent repolarization during pacing, the atrio-ventricular (AV) conduction time (defined as the interval between the atrial pace pulse and the start of the ventricular MAP) during pacing, and the heart rate (defined as the RR interval during sinus rhythm). Systolic and diastolic blood pressure were measured in order to judge the haemodynamic status of the anaesthetised animal. Further, the ECG was checked for arrhythmias and/or morphological changes.

The mean of the two control recordings was set to zero and the effects recorded after consecutive doses of test substance were expressed as percentage changes from this value. By plotting these percentage values against the cumulative dose administered before each recording, it was possible to construct dose-response curves. In this way, each experiment generated three dose-response curves, one for MAP duration, one for AV-conduction time and one for the sinus frequency (RR interval). A mean curve of all experiments performed with a test substance was calculated, and potency values were derived from the mean curve. All dose-response curves in these experiments were constructed by linear connection of the data points obtained. The cumulative dose prolonging the MAP duration by 10% from the baseline was used as an index to assess the class III electrophysiological potency of the agent under investigation (D_{10}).

PRJ99-06-16

The invention is illustrated by way of the following examples.

Examples

General Experimental Procedures

Mass spectra were recorded on a Finnigan MAT TSQ 700 triple quadrupole mass spectrometer equipped with an electrospray interface (FAB-MS) and VG Platform II mass spectrometer equipped with an electrospray interface (LC-MS), a Hewlett Packard model 6890 gas chromatograph connected to a Hewlett-Packard model 5973A mass spectrometer *via* a Hewlett Packard HP-5-MS GC column, or a Shimadzu QP-5000 GC/mass spectrometer (CI, methane). ^{1}H NMR and ^{13}C NMR measurements were performed on a BRUKER ACP 300 and Varian UNITY plus 400 and 500 spectrometers, operating at ^{1}H frequencies of 300, 400 and 500 MHz respectively, and at ^{13}C frequencies of 75.5, 100.6 and 125.7 MHz respectively. Alternatively, ^{13}C NMR measurements were performed on a BRUKER ACE 200 spectrometer at a frequency of 50.3 MHz.

Rotamers may or may not be denoted in spectra depending upon ease of interpretation of spectra. Unless otherwise stated, chemical shifts are given in ppm with the solvent as internal standard.

Example 1

tert-Butyl 7-[4-(4-cyanophenyl)-4-(3,4-dimethoxyphenoxy)butyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

(i) 3,7-Dibenzyl-3,7-diazabicyclo[3.3.1]nonane-9-one

The sub-title compound was prepared according to the procedure described in *J. Org. Chem.*, 41(9), 1976, pp. 1593-1597.

PAU98-06-16

(ii) 3,7-Dibenzyl-3,7-diazabicyclo[3.3.1]nonane

The sub-title compound was prepared according to the procedure described in *J. Org. Chem.*, **41**(9), 1976, pp. 1593-1597, using 3,7-dibenzyl-3,7-diazabicyclo[3.3.1]nonane-9-one (from step (i) above) in place of N-benzyl-N'-methylbispidone.

(iii) 3-Benzyl-3,7-diazabicyclo[3.3.1]nonane

A solution of 3,7-dibenzyl-3,7-diazabicyclo[3.3.1]nonane (from step (ii) above; 97 g; 6.4 mmol) in aqueous ethanol (95%) was hydrogenated over 5% Pd/C at 1 atm. until tlc indicated that the reaction was complete. The catalyst was removed by filtration through a pad of Celite®, and the filtrate concentrated under reduced pressure to give the sub-title compound in quantitative yield.

^{13}C NMR in $CDCl_3$: δ 30.1, 33.4, 36.0, 52.5, 59.6, 64.3, 126.9, 128.3, 128.7, 138.8

(iv) *tert*-Butyl 7-benzyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Di-*tert*-butyl dicarbonate was added slowly to a solution of 3-benzyl-3,7-diazabicyclo[3.3.1]nonane (from step (iii) above; 60 g; 277 mmol) in THF (600 mL). The reaction was stirred at rt until all of the starting material had been consumed (as indicated by tlc). The solvent was then removed under reduced pressure to give a quantitative yield of the sub-title compound.

(v) *tert*-Butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The sub-title compound was prepared in quantitative yield according to the procedure described in step (iii) above, using *tert*-butyl 7-benzyl-3,7-

diazabicyclo[3.3.1]nonane-3-carboxylate (from step (iv) above) in place of 3,7-dibenzyl-3,7-diazabicyclo[3.3.1]nonane.

^{13}C NMR in $CDCl_3$: δ 28.05, 28.29, 31.33, 48.35, 49.11, 51.53, 79.34, 155.16

(vi) 4-(1-{[1-(*tert*-Butyl)-1,1-dimethylsilyl]oxy}-3-butenyl)benzonitrile

Imidazole (11.5 g; 170 mmol) and *tert*-butyldimethylsilyl chloride (12 g; 80 mmol) were added to a stirred solution of 1-(*p*-cyanophenyl)-3-buten-1-ol (11.5 g; 87 mmol) in DMF (50 mL), and the reaction mixture was stirred under an inert atmosphere (N_2) for 10 h. The solvent was then evaporated and the residue partitioned between water and diethyl ether. The organic layer was separated, dried, concentrated and subjected to column chromatography (CH_2Cl_2) to give the sub-title compound in a 86% yield.

(vii) 4-(1-{[1-(*tert*-Butyl)-1,1-dimethylsilyl]oxy}-4-hydroxybutyl)-benzonitrile

Borane-methyl sulfide complex (13 mL; 2 M; 26 mmol) was added to a cooled (0°C), stirred solution of 4-(1-{[1-(*tert*-butyl)-1,1-dimethylsilyl]oxy}-3-butenyl)benzonitrile (from step (vi) above; 15.2 g; 53 mmol) in THF (100 mL). After addition was complete, the reaction was allowed to warm to rt, and stirring was continued until all of the starting material was consumed (as indicated by tlc). The temperature was then lowered to 0°C again, and an aqueous solution of sodium perborate tetrahydrate (19 g; 123 mmol in 55 mL) was added. The reaction mixture was stirred for a further 12 h at rt before brine (100 mL) and diethyl ether (150 mL) were added. The organic layer was then separated, dried,

concentrated and subjected to column chromatography (hexane:EtOAc; 1:1) to give the title compound in 85% yield.

(viii) 4-{[1-(*tert*-Butyl)-1,1-dimethylsilyl]oxy}-4-(4-cyanophenyl)butyl methanesulfonate

Methanesulfonyl chloride (7.9 g; 69 mmol) and triethylamine (10.3 g; 102 mmol) were added to a cooled (0°C), stirred solution of 4-(1-{[1-(*tert*-butyl)-1,1-dimethylsilyl]oxy}-4-hydroxybutyl)benzonitrile (from step (vii) above; 20.8 g; 69 mmol) in CH_2Cl_2 (200 mL). The reaction was allowed to warm to rt until all of the starting material was consumed (as indicated by tlc). Water (200 mL) was added and the organic layer was separated, dried and concentrated to give the title compound in 98% yield.

(ix) *tert*-Butyl-7-[4-(4-cyanophenyl)-4-{[1-(*tert*-butyl)-1,1-dimethylsilyl]-oxy}-butyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Anhydrous potassium carbonate (0.96 g; 7 mmol) and *tert*-butyl-3,7-diazbicyclo[3.3.1]nonane-3-carboxylate (from step (v) above; 1.13 g; 5 mmol) were added to a stirred solution of 4-{[1-(*tert*-butyl)-1,1-dimethylsilyl]oxy}-4-(4-cyanophenyl)butyl methanesulfonate (from step (viii) above; 1.92 g; 5 mmol) in MeCN (5 mL) under an inert atmosphere (N_2). After addition was complete, the reaction was stirred at rt for 10 h. The solvent was evaporated and the residue partitioned between CH_2Cl_2 and $NaHCO_3$ (aq.), then the organic layer was separated, dried and concentrated. Purification using column chromatography (CH_2Cl_2:MeOH; 19:1) gave the title compound in 96% yield.

PRV99-06-16

(x) *tert*-Butyl 7-[4-(4-cyanophenyl)-4-hydroxybutyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

Tetrabutylammonium fluoride (0.95 mmol) was added to a stirred solution of *tert*-butyl 7-[4-(4-cyanophenyl)-4-{[1-(*tert*-butyl)-1,1-dimethylsilyl]-oxy}butyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (ix) above; 0.44 g; 0.85 mmol) in THF (5 mL), and the reaction mixture stirred at rt for 2 h. The solvent was then evaporated and the residue subjected to column chromatography (MeCN:MeOH; gradient 0 - 10% MeOH) to give the title compound in 70 % yield.

ESI-MS: m/z = 400.0 ($M + H^+$)

^{13}C NMR in $CDCl_3$: δ 22.26, 28.37, 30.10, 37.26, 37.63, 47.68, 48.53, 57.73, 58.34, 59.12, 72.49, 78.95, 110.03, 119.05, 126.59, 131.71, 151.05, 155.58

(xi) *tert*-Butyl 7-[4-(4-cyanophenyl)-4-(3,4-dimethoxyphenoxy)butyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Triphenylphosphine (1.11 g; 4.25 mmol) in 5 mL CH_2Cl_2 and 1,1'-(azodicarbonyl)dipiperidine (1.07 g; 4.25 mmol) in 15 mL CH_2Cl_2 were added to a stirred solution of 3,4-dimethoxyphenol (0.65 g; 4.25 mmol) and *tert*-butyl 7-[4-(4-cyanophenyl)-4-hydroxybutyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate (from step (x) above; 0.85 g; 2.12 mmol). After 3 h, the precipitate was filtered off, and the filtrate concentrated. The residue was dissolved in aqueous tartaric acid (1 M; 25 mL) and the solution was washed with diethyl ether. The aqueous phase was made basic with and extracted again with diethyl ether. The organic layer from this second extraction was separated, dried (Na_2SO_4) and then concentrated to give the title compound in 21% yield.

Example 2

tert-Butyl 7-[4-(4-cyanophenyl)-4-(4-hydroxyphenoxy)butyl]-3,7-diaza-bicyclo[3.3.1]nonane-3-carboxylate

(i) 4-{1-[4-(Tetrahydro-2*H*-pyran-2-yloxy)phenoxy]-3-butenyl}benzonitrile

4-(Tetrahydro-2*H*-pyran-2-yloxy)phenol (19.0 g; 0.1 mol) and 4-(1-hydroxy-3-butenyl)benzonitrile (17.8 g; 0.1 mol) was mixed in toluene, and cooled to 0°C (under nitrogen). TBP (22.9 g; 0.11 mol) was added, followed by ADDP. The mixture was stirred at rt overnight, filtered, and evaporated. Purification by chromatography on silica gave 24 g (68.7%) of the desired compound.

(ii) 4-{4-Hydroxy-1-[4-(tetrahydro-2*H*-pyran-2-yloxy)phenoxy]butyl}-benzonitrile

4-{1-[4-(Tetrahydro-2*H*-pyran-2-yloxy)phenoxy]-3-butenyl}benzonitrile (from step (i) above; 4.6 g; 13 mmol) was dissolved in dry THF (50 mL) under argon and cooled to -5°C. Borane-methylsulfide complex (BH_3 x SMe_2) (3.5 mL of a 2 M solution in ether) was added dropwise at 0 to 5°C. The mixture was stirred at that temperature for 1.5 h. After 4 h at rt, tlc showed that the reaction was complete. The reaction mixture was quenched with 14 mL of H_2O and 5 g of $NaBO_3$. The mixture was stirred overnight, the solvent decanted off, and the residue treated with ether and decanted. The combined organic fractions were washed with brine, dried (Na_2SO_4), and evaporated. The crude product was purified by chromatography on silica (*iso*-propanol:ethyl acetate:heptane; 5:20:70). Yield: 2.44 g (58%).

(iii) 4-(4-Cyanophenyl)-4-[4-(tetrahydro-2*H*-pyran-2-yloxy)phenoxy]butyl methanesulfonate

The sub-title compound was prepared in quantitative yield from 4-{4-hydroxy-1-[4-(tetrahydro-2*H*-pyran-2-yloxy)phenoxy]butyl}benzonitrile (from step (ii) above) according to the procedure described in Example 1 (viii) above.

(iv) *tert*-Butyl 7-{4-(4-cyanophenyl)-4-[4-(tetrahydro-2*H*-pyran-2-yloxy)-phenoxy]butyl}-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The sub-title compound was prepared in 75% yield from 4-(4-cyanophenyl)-4-[4-(tetrahydro-2*H*-pyran-2-yloxy)phenoxy]butyl methanesulfonate (from step (iii) above) and *tert*-butyl 3,7-diazabicyclo[3.3.1]nonane (see Example 1(v) above) according to the method described in Example 1 (ix) above.

(v) *tert*-Butyl 7-[4-(4-cyanophenyl)-4-(4-hydroxyphenoxy)butyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

tert-Butyl 7-{4-(4-cyanophenyl)-4-[4-(tetrahydro-2*H*-pyran-2-yloxy)-phenoxy]butyl}-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (iv) above; 2.33 g; 4.0 mmol), was dissolved in THF (40 mL), acetic acid (20 mL) and H_2O (10 mL). The mixture was stirred at 35°C for 2 days. The mixture was made basic with 10 M NaOH (whilst cooling). Extraction with DCM, separation of the organic layer, evaporation of the solvent and chromatography on silica (CH_3CN) gave 1.43 g (72%) of the title compound.

ESI-MS: m/z = 492.1 (MH^+)

^{13}C NMR in $CDCl_3$: δ 22.66, 28.55, 28.88, 29.19, 31.51, 35.50, 35.77, 47.79, 48.88, 57.70, 57.88, 58.69, 58.78, 59.54, 78.93, 80.12, 110.97, 115.97, 117.03, 118.78, 126.97, 132.24, 147.80, 150.80, 151.27, 155.34

Example 3

tert-Butyl 7-[4-(4-cyanophenyl)-4-(4-pyridinylmethoxy)butyl]-3,7-diaza-bicyclo[3.3.1]nonane-3-carboxylate

NaH (0.059 g; 55% suspension in oil; 1.35 mmol) was washed with petroleum ether (fraction 40/60). 2 mL of DMSO was added. *tert*-Butyl 7-[4-(4-cyanophenyl)-4-hydroxybutyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (see Example 1(x) above; 0.54 g; 1.05 mmol) dissolved in 10 mL of DMF was added dropwise at 0°C. After 15 minutes, 4-pyridinylmethyl chloride (0.17 g; 1.05 mmol) was added dropwise at 0°C. The mixture was stirred at 0°C for 30 minutes, then at rt overnight. The reaction mixture was diluted with water and extracted with ethyl acetate:toluene (1:1). The organic layer was separated and washed with brine and water. Evaporation *in vacuo* gave 0.56 g of crude product. Purification on silica (DCM:10% MeOH) gave 0.17 g (26%) of the title compound.

ESI-MS: m/z = 491.0 (MH^+)

^{13}C NMR in $CDCl_3$: δ 22.35, 28.38, 28.74, 28.95, 31.25, 35.10, 47.51, 48.58, 57.89, 58.50, 59.08, 59.22, 68.92, 78.24, 81.42, 81.55, 111.26, 118.57, 121.52, 127.75, 132.19, 147.12, 147.47, 149.57, 154.86

Example 4

The title compound of Examples 1 to 3 above was tested in Test A above and was found to exhibit a D_{10} value of more than 6.0.

PRV99-06-16

127

Abbreviations

ADDP =	1,1'-(azodicarbonyl)dipiperidine
aq. =	aqueous
atm. =	atmospheres
DMF =	dimethylformamide
DMSO =	dimethylsulfoxide
Et =	ethyl
EtOAc =	ethyl acetate
ESI =	electron spray interface
FAB =	fast atom bombardment
h =	hours
IPA =	*iso*-propanol
LC =	liquid chromatography
HPLC =	high performance liquid chromatography
Me =	methyl
MeCN =	acetonitrile
MeOH =	methanol
min. =	minutes
MS =	mass spectroscopy
NADPH =	nicotinamide adenine dinucleotide phosphate, reduced form
NMR =	nuclear magnetic resonance
Pd/C =	palladium on carbon
rt. =	room temperature
sat. =	saturated
TBP =	tributyl phosphine
THF =	tetrahydrofuran
tlc =	thin layer chromatography


PRV99-06-16

Prefixes *n, s, i* and t have their usual meanings: normal, iso, secondary and tertiary.

PRV99-06-16

Claims

1. A compound of formula I,



I

wherein

R^1 represents C_{1-12} alkyl, $-(CH_2)_a$-aryl, or $-(CH_2)_a$-Het^1 (all of which are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, halo, cyano, nitro, C_{1-4} alkyl and/or C_{1-4} alkoxy);

represents 0, 1, 2, 3, or 4;

Het^1 represents a five to ten-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

X represents O or S;

R^{5a} and R^{5b} independently represent H or C_{1-3} alkyl;

R^2 and R^3 independently represent H, C_{1-4} alkyl (optionally substituted and/or terminated with one or more nitro or cyano groups), OR^7, $N(R^{7a})R^{7b}$, $OC(O)R^8$ or together form $-O-(CH_2)_2-O-$, $-(CH_2)_3-$, $-(CH_2)_4-$ or $-(CH_2)_5-$;

R^7 and R^8 independently represent H, C_{1-6} alkyl or $-(CH_2)_b$-aryl (which latter two groups are optionally substituted and/or terminated by one or more substituents selected from -OH, halo, cyano, nitro, C_{1-4} alkyl and/or C_{1-4} alkoxy);

R^{7a} and R^{7b} independently represent H or C_{1-6} alkyl;

b represents 0, 1, 2, 3 or 4;

5.726

Traducción Oficial No.

María Luisa Bryant de Rodrigo
Intérprete Oficial
Ref. No. 0743 del Min. de Justicia

R^4 represents H or C_{1-6} alkyl;

R^9 represents $-C(O)R^{10}$, C_{1-6} alkyl, $-(CH_2)_d$-aryl or $-(CH_2)_d$-Het^2 (which latter three groups are optionally substituted by one or more substituents selected from -OH, halo, cyano, nitro, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)R^{11}$, $C(O)OR^{12}$ and/or $-N(H)S(O)_eR^{13}$);

R^{10}, R^{11} and R^{12} independently represent H, C_{1-6} alkyl, Het^3 or $-(CH_2)_f$-aryl (which latter three groups are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl, C_{1-6} alkoxy, $C(O)R^{14}$, $C(O)OR^{15}$ and/or $N(H)S(O)_2R^{16}$);

R^{13} represents C_{1-6} alkyl or $-(CH_2)_g$-aryl (both of which are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from halo, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

R^{14} and R^{15} independently represent H, C_{1-6} alkyl or aryl;

R^{16} represents C_{1-6} alkyl or aryl;

PRUEBA 06.16

e represents 0, 1 or 2;

d, f and g independently represent 0, 1, 2, 3 or 4;

Het^2 and Het^3 independently represent five to ten-membered heterocyclic rings containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

R^6 represents one or more optional substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl (optionally terminated by $N(H)C(O)OR^{18a}$), C_{1-6} alkoxy, $-C(O)N(H)R^{19}$, $-NHC(O)N(H)R^{20}$, $-N(H)S(O)_2R^{21}$ and/or $-OS(O)_2R^{22}$;

R^{19} and R^{20} independently represent H or C_{1-6} alkyl;

R^{18a}, R^{21} and R^{22} independently represent C_{1-6} alkyl;

5726

A represents a single bond, C_{1-6} alkylene or $-(CH_2)_jC(H)(OR^{23})(CH_2)_k-$ (in which latter group, the $-(CH_2)_j-$ group is attached to the bispidine nitrogen atom and which latter two groups are optionally substituted by one or more -OH groups);

B represents a single bond, C_{1-4} alkylene, $-(CH_2)_mN(R^{24})-$, $-(CH_2)_mS(O)_n-$, $-(CH_2)_mO-$ (in which three latter groups, the $-(CH_2)_m-$ group is attached to the carbon atom bearing OR^9 and R^4), $-C(O)N(R^{24})-$ (in which latter group, the -C(O)- group is attached to the carbon atom bearing OR^9 and R^4), $-N(R^{24})C(O)O(CH_2)_m-$ or $-N(R^{24})(CH_2)_m-$ (in which latter two groups, the $N(R^{24})$ group is attached to the carbon atom bearing OR^9 and R^4);

j represents 1, 2, 3 or 4;

k and m independently represent 0, 1, 2, 3 or 4;

n represents 0, 1 or 2;

R^{23} represents H, C_{1-6} alkyl or $C(O)R^{25}$;

R^{24} represents H or C_{1-6} alkyl;

R^{25} represents H, C_{1-6} alkyl, Het^4 or $-(CH_2)_p$-aryl (which latter two groups are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

Het^4 represents a five to ten-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

p represents 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable derivative thereof;

provided that m does not represent 0 when B represents $-(CH_2)_mN(R^{24})-$, $-(CH_2)_mS(O)_n-$ or $-(CH_2)_mO-$.

Ref. Especial. OFICIAL No. 5.726
María Luisa Brigard de Restrepo
Intérprete Oficial
con No. 8703 del Min. de Justicia

2. A compound as claimed in Claim 1, wherein R^1 represents optionally substituted $-(CH_2)_a$-phenyl, in which a is 0, 1, 2 or 3, or optionally substituted, optionally unsaturated, linear, branched or cyclic, C_{1-8} alkyl (which latter group may also be interrupted by an oxygen atom).

3. A compound as claimed in Claim 1 or Claim 2, wherein R^2 represents H.

4. A compound as claimed in any one of the preceding claims, wherein R^3 represents H.

5. A compound as claimed in any one of the preceding claims, wherein R^4 represents H or C_{1-2} alkyl.

6. A compound as claimed in any one of the preceding claims, wherein R^{5a} and R^{5b} either both represent H or both represent methyl.

7. A compound as claimed in any one of the preceding claims, wherein R^6 represents one or more substituents selected from C_{1-6} alkyl, cyano, nitro, amino, $C(O)N(H)R^{19}$ and/or $-N(H)S(O)_2R^{21}$.

8. A compound as claimed in any one of the preceding claims, wherein X represents O.

9. A compound as claimed in any one of the preceding claims, wherein A represents a single bond or linear, or branched, C_{1-6} alkylene (which group is also optionally interrupted by O).

OFFICIAL No. 5.726
María Luisa Brigard de Restrepo
Intérprete Oficial
Res. No. 0793 del Min. de Justicia

10. A compound as claimed in any one of the preceding claims, wherein B represents a single bond, C_{1-4} alkylene, $-(CH_2)_mO-$ or $-(CH_2)_mN(R^{24})-$ (in which latter two cases m is 1, 2 or 3).

11. A compound as claimed in any one of the preceding claims, wherein R^9 represents $C(O)R^{10}$ (in which R^{10} represents C_{1-3} alkyl or optionally substituted Het^3); C_{1-3} alkyl; optionally substituted phenyl; or optionally substituted $-(CH_2)_d-Het^2$ (in which d is 0, 1 or 2).

12. A pharmaceutical formulation including a compound as defined in any one of Claims 1 to 11 in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

PRV90-06-16

13. A pharmaceutical formulation for use in the prophylaxis or the treatment of an arrhythmia, comprising a compound as defined in any one of Claims 1 to 11.

14. A compound as defined in any one of Claims 1 to 11 for use as a pharmaceutical.

15. A compound as defined in any one of Claims 1 to 11 for use in the prophylaxis or the treatment of an arrhythmia.

16. The use of a compound as defined in any of one Claims 1 to 11 as active ingredient in the manufacture of a medicament for use in the prophylaxis or the treatment of an arrhythmia.

5.726
Maria Luisa Brigard de Restrepo
Intérprete Oficial


17. The use as claimed in Claim 16, wherein the arrhythmia is an atrial or a ventricular arrhythmia.

18. A method of prophylaxis or treatment of an arrhythmia which method comprises administration of a therapeutically effective amount of a compound as defined in any one of Claims 1 to 11 to a person suffering from, or susceptible to, such a condition.

19. A process for the preparation of a compound of formula I as defined in Claim 1 which comprises:

(a) reaction of a compound of formula II,

PRV/98.06.16




II

wherein R^2, R^3, R^4, R^{5a}, R^{5b}, R^6, R^9, A and B are as defined in Claim 1 with a compound of formula III,

$$R^1XC(O)L^1 \qquad \text{III}$$


wherein L^1 represents a leaving group and R^1 and X are as defined in Claim 1;

(b) reaction of a compound of formula IV



IV

wherein R^1, R^2, R^3, R^{5a}, R^{5b} and X are as defined in Claim 1, with a compound of formula V,




V

wherein L^2 represents a leaving group and R^4, R^6, R^9, A and B are as defined in Claim 1;

(c) for compounds of formula I in which one of R^2 and R^3 represents H or OH and the other represents H, reduction of a corresponding compound of formula VI,


PHARMACHEM. OFFICIAL No. 5.756
María Luisa Brigard de Restrepo
Intérprete Oficial



VI

wherein R^1, R^4, R^{5a}, R^{5b}, R^6, R^9, A, B and X are as defined in Claim 1;

(d) for compounds of formula I in which R^9 represents optionally substituted C_{1-6} alkyl, optionally substituted $-(CH_2)_d$-aryl or optionally substituted $-(CH_2)_d$-Het^2, reaction of a compound of formula VII,



VII


wherein R^1, R^2, R^3, R^4, R^{5a}, R^{5b}, R^6, A and B are as defined in Claim 1 with a compound of formula VIII,

$R^{9a}OH$ VIII

wherein R^{9a} represents optionally substituted C_{1-6} alkyl, optionally substituted $-(CH_2)_d$-aryl or optionally substituted $-(CH_2)_d$-Het^2 and d and Het^2 are as defined in Claim 1;

(e) for compounds of formula I in which R^9 represents optionally substituted C_{1-6} alkyl, optionally substituted $-(CH_2)_d$-aryl or optionally substituted $-(CH_2)_d$-Het^2, reaction of a compound of formula IX,

PHARMACIST. OFFICIAL No. 5.726
María Luisa Brizuela de Restrepo
Intérprete Oficial
Leyes del Min. de Justicia



IX

wherein L^2 is as defined above and R^1, R^2, R^3, R^4, R^{5a}, R^{5b}, R^6, A and B are as defined in Claim 1 with a compound of formula VIII as defined above;

(f) for compounds of formula I in which R^9 represents $C(O)R^{10}$ and R^{10} is as defined in Claim 1, reaction of a corresponding compound of formula VII as defined above with a compound of formula X,

$$R^{10}CO_2H \qquad X$$

wherein R^{10} is as defined in Claim 1;

(g) for compounds of formula I in which R^2 and/or R^3 represent represents $OC(O)R^8$ and R^8 is as defined in Claim 1, coupling of a corresponding compound of formula I in which R^2 and/or R^3 (as appropriate) represents OH and a compound of formula XI,

$$R^8CO_2H \qquad XI$$

wherein R^8 is as defined in Claim 1;

(h) for compounds of formula I which are bispidine-nitrogen N-oxide derivatives, oxidation of the corresponding bispidine nitrogen of a corresponding compound of formula I;

(i) for compounds of formula I which are C_{1-4} alkyl quaternary ammonium salt derivatives, in which the alkyl group is attached to a bispidine

PRV99-06-16

nitrogen, reaction, at the bispidine nitrogen, of a corresponding compound of formula I with a compound of formula XII,

$$R^xHal \qquad XII$$

wherein R^x represents C_{1-4} alkyl and Hal represents Cl, Br or I;

(j) reaction of a compound of formula II, as defined above, with a compound of formula XIII,

$$R^1XH \qquad XIII$$

wherein R^1 and X are as defined in Claim 1, in the presence of 1,1'-carbonyldiimidazole;

(k) for compounds of formula I in which one or both of R^2 and R^3 represent $-N(R^{7a})R^{7b}$ in which one or both or R^{7a} and R^{7b} represents C_{1-6} alkyl, alkylation of a corresponding compound of formula I in which R^2 and/or R^3 represent $-N(R^{7a})R^{7b}$ (as appropriate) in which R^{7a} and/or R^{7b} (as appropriate) represent H, using a compound of formula XIIIA,

$$R^{7c}L^1 \qquad XIIIA$$

wherein R^{7c} represents C_{1-6} alkyl and L^1 is as defined above;

(l) conversion of one R^6 substituent to another; or

(m) deprotection of a protected derivative of a compound of formula I as defined in Claim 1.


20. A compound of formula II as defined in Claim 19 or a protected derivative thereof.

21. A compound of formula IV as defined in Claim 19, or a protected derivative thereof, provided that when R^{5a} and R^{5b} both represent H, then at least one of R^2 and R^3 represents OR^7, $OC(O)R^8$ or C_{1-4} alkyl, which alkyl group is substituted and/or terminated with one or more nitro or cyano groups.

PRV99.06.16

22. A compound of formula VI as defined in Claim 19, or a protected derivative thereof.

23. A compound of formula XV,




XV

5.726

wherein R^4, R^{5a}, R^{5b}, R^9, A and B are as defined in Claim 1, or a protected derivative thereof.

24. A process for the preparation of a compound formula VI, XV, XVII or XXIII, as defined herein, which comprises reaction of a compound of formula XXV,




XXV

wherein R^z represents H or -C(O)XR^1 and R^1, R^{5a}, R^{5b} and X are as defined in Claim 1, or a protected derivative thereof, with (as appropriate) either:

(1) a compound of formula XXVI,

PRV99-08-16



XXVI

TRADUCCIÓN OFICIAL No. 5726
Interprete Oficial

or a protected derivative thereof, wherein R^4, R^6, R^9, A and B are as hereinbefore defined; or


(2) NH_3 (or a protected derivative thereof),

in all cases in the presence of a formaldehyde.

PRV 99-06-16

ABSTRACT

There is provided compounds of formula I,



I

wherein R^1, R^2, R^3, R^4, R^{5a}, R^{5b}, R^6, R^9, X, A and B have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

159

143

TRADUCCION OFICIAL No. 142

LEGALIZACION DE UN DOCUMENTO PRESENTADO SIMULTÁNEAMENTE EN INGLES Y ESPAÑOL. TRASPASO DE LA INVENCIÓN DENOMINADA ***NUEVOS COMPUESTOS DE BISPIDINA UTILES EN EL TRATAMIENTO DE ARRITMIAS CARDIACAS*** *A FAVOR DE* ***ASTRAZENECA AB.***

Firmado: **Marianne Frantsi**

Firmado: **Kurt-Jürgen Hoffman**

Firmado: **Gert Strandlund**

Sello que a la letra dice:

Yo, el suscrito, Anne-Marie Bonde, Notario Público de la Ciudad de Estocolmo, Suecia, certifico que MARIANNE FRANTSI; KURT- JURGEN HOFFMANN Y GERT STRANDLUND, han expedido y firmado el anterior documento.

Estocolmo: 2000-05-26

Firmado: MARIE-ANNE BONDE

Sello en papel dorado del Notario Público de Estocolmo, Anne-Marie Bonde.

ANIA SALAMANCA DE ABREU
TRADUCTORA OFICIAL
MES MINJUSTICIA 3288

160

144

CERTIFICADO NOTARIAL (INDIVIDUAL)

CERTIFICADO PRESENTADO SIMULTANEAMENTE EN INGLES Y ESPAÑOL.

Firmado: **(Anne-Marie Bonde)**
Notario Público

Sello: Notario Publico
Anne-Marie Bonde
Estocolmo

CONSULADO DE COLOMBIA

ESTOCOLMO, SUECIA

No. 001949

CERTIFICA la firma del señor **Anne-Marie Bonde,** como Notario Público de Estocolmo, Suecia.

Fecha: mayo 30, 2000.

Firmado: **MARIA SMITH RUEDA**
Encargada de las Funciones Consulares

Hay sello del Consulado de Colombia en Estocolmo

CERTIFICACION EN ESPAÑOL DEL CONSULADO DE COLOMBIA EN ESTOCOLMO, SUECIA SOBRE EL CARGO DE LOS REPRESENTATES DE ASTRAZENECA AB.

Firmado: **MARIA SMITH RUEDA**
Encargada de las Funciones Consulares

Hay sello del Consulado de Colombia en Estocolmo.

MARIA SALAMANCA DE KREUZ
TRADUCTORA
RES. MINJUSTICIA

MINISTERIO DE RELACIONES EXTERIORES

CERTIFICA la firma y las funciones del funcionario consular **María Smith Rueda,** bajo el número **182198**, el día junio 14 del 2000.

Firmado: (Firma ilegible)
Jefe de Legalizaciones

Santafé de Bogotá, D.C.

KATIA SALAMANCA DE ARAEU
TRADUCTORA DE
DES. MINJUSTICIA

MINISTERIO DE RELACIONES EXTERIORES
284303
KATIA SALAMANCA
CONSULTA DE LEGALIZACIONES
PRESENTADO EN LA OFICINA DE LEGALIZACIONES

NO SE ASUME RESPONSABILIDAD EL TEXTO
2000 JUN 20 P M 4:07
LEGALIZADORES
SANTAFE DE BOGOTA D.C.

X67
146

ASSIGNMENT

The undersigned,

Marianne Frantis, Kurt-Jürgen Hoffmann and Gert Strandlund all

domiciled in
AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden
and

hereby state under oath to be the sole and true inventor of

NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS

We state as well that We assign, without reservations or limitation, in favor of

AstraZeneca AB

a corporation organized and existing under the laws of

Sweden

domiciled in

S-151 85 Södertälje, Sweden

all rights inherent to said invention, and that the above mentioned corporation hereby is enabled to apply, in its name, for the corresponding patent in the Republic of Colombia.

Marianne Frantsi

Gert Strandlund

TRASPASO

abajo firmado

Marianne Frantis, Kurt-Jürgen Hoffmann y Gert Strandlund all.

domiciliado en

AstraZeneca R&D Mölndal, S-431 83 Mölndal, Suecia
y

declara bajo juramento ser único y verdadero inventor de.

NUEVOS COMPUESTOS BISPIDINA UTILES EN EL TRATAMIENTO DE ARRITMIAS CARDIACAS.

Declara asimismo que cede y transfiere sin reserva ni limitación, a favor de la sociedad

ASTRAZENECA AB

organizada y existente de conformidad con la leves de

SUECIA

domiciliada en

S-151 85 Södertalje, Suecia

Todos los derechos inherentes a dicha invención y que la citada sociedad queda facultada para solicitar en su nombre la patente correspondiente en la República de Colombia.

Kurt-J. Hoffmann

Kurt-Jürgen Hoffmann

I, the undersigned, Anne-Marie Bonde, Notary Public of the City of Stockholm, Sweden, certify that
MARIANNE F R A N T S I; GERT S T R A N D L U N D and Kurt-JURGEN H O F F M A N N,
~~duly authorized to sign for~~
~~AstraZeneca AB~~

have issued and signed the foregoing document,
Kr. 250:- **Stockholm,** 2000-05-26
Stämpelavgift: **Enligt lag:**

NOTARIUS PUBLICUS STOCKHOLM
ANNE-MARIE BONDE

83

CERTIFICADO NOTARIAL (INDIVIDUO)

A los 26 días del mes de Mayo 2000 ~~MX~~, compareci personalmente ante mi, Notario Publico,

MARIANNE F R A N T S I,
GERT S T R A N D L U N D y
KURT-JÜRGEN H O F F M A N N

a quien doy fé de conocer y me consta que la persona descrita y firmante del documento que precede, declarado ante mí que otorga el mismo para los fines y propósitos que en él se expresan.

De oficio:

Anne-Marie Bonde
Notario Público

NOTARIAL CERTIFICATE (INDIVIDUAL)

On this day of 2 personally appeared before me, a Notary Public,

to me known and known to me to be the person described in and who executed the foregoing document, and duly acknowledged to me that executed the same for the uses and purposes therein expressed.

EL CONSULADO DE COLOMBIA EN
ESTOCOLMO, SUECIA

Fecha 2000 -05- 30 No: .....

Previa la confrontación correspondiente DA FE de que la firma que aparece en este documento es similar a la REGISTRADA aquí por Anne-Marie Bonde, Notario Público, Estocolmo, Suecia.

Encargada de las Funciones Consulares

PAGADO
Impuesto de Timbre
Siete ... 7
Tasa Consular
Quince ... 15

MINISTERIO DE RELACIONES EXTERIORES

Industria y Comercio
SUPERINTENDENCIA

148

2do. EXAMEN DE FORMA PATENTE DE INVENCION

Folio 164

Radicación no 00-44225

Concepto Técnico no 727

Clasificación Internacional de Patentes A61K31/16 // 31/015

...examen de acuerdo a lo establecido en el Art. 38 de la Decisión 486 se determinó que

147

EL CONSUL DE COLOMBIA

En Estocolmo, Suecia

C E R T I F I C A :

Que el señor Marianne Fraentsi, Gert Strandlund, Kurt-Jören Hoffmann quien firma el documento que antecede ejercía para la fecha el cargo de representantes

de la Sociedad Astra Zeneca AB

que existe de confirmidad con las leyes de Suecia.

según se acreditó con los documentos que tuve a la vista.

Fecha 2000-05-30 No: 106

M. Smith R

MARIA SMITH RUEDA
Encargada de las Funciones Consulares

PAGADO
Impuesto de Timbre
Siete dólares US$ 7
Derechos Consulares
Quince dólares US$ 15

ESTOCOLMO

SI [X] NO [ ] La pri...

SI [X] NO [ ] CUMPLE LOS REQUISITOS TÉCNICOS

OBSERVACIONES Y OTROS: SI [ ] NO [ ] ver hoja(s) anexa(s)

1. Se presentan nuevas páginas 52, 53 y 54 del texto de las reivindicaciones que reemplazan las originalmente presentadas (Folio 71 a 73)
2. Se anexan las artes finales de la estructura química principal según lo requerido.

EXAMINADOR TÉCNICO
202040

Bogotá D. C., Abril 10, 2002.

Carrera 13 No. 27-00 Piso 5 y 10
Conmutador: 334 12 21-2-3-4
Fax: 281 31 25 e-mail: info@sic.gov.co
Santa Fe de Bogotá D.C. - Colombia

Industria y Comercio
SUPERINTENDENCIA

2020
Bogotá D.C.,

Doctor:
José Antonio Lloreda
Apoderado

REFERENCIA:	**Radicación N°**	**00-44225**
	Trámite	**002**
	Evento	**001**
	Actuación	**416**
	Oficio N°	**1020**
	Folios	**001**

Teniendo en cuenta que la solicitud de privilegio de patente de invención que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en los artículos 26 y 27 de la Decisión 486 de la Comisión del Acuerdo de Cartagena, y en las demás disposiciones vigentes sobre la materia, se envía el extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial, conforme lo establece el artículo 40 de la misma Decisión.

Cúmplase
Dado en Bogotá D.C., a los

ALIX CARMENZA CÉSPEDES DE VERGEL
Jefe de la División de Nuevas Creaciones

Bogotá, DC, 04-05-05 El extracto de esta solicitud fue publicado en el número 518 de la Gaceta de Propiedad Industrial, de fecha 30-07-2002 . El término hábil señalado por la ley expiró el 25-10-2002 y SI ___ NO X se presentaron oposiciones por parte de terceros.

Carrera 13 No. 27-00 Pisos 5, 7 y 10
Conmutador: 382 0840
Fax: 382 2695
E-mail: info@sic.gov.co
www.sic.gov.co
Bogotá, D.C., Colombia